Table 1.
Characteristics of the study population.
| Patienta | Age | Gender | Tonsillectomy indication | tCD207 DCsb | CD1c DCsb | CD141/Clec9A DCsb | pDCsb | Macrophagesb | EBV statusc |
|---|---|---|---|---|---|---|---|---|---|
| Child 1 | 1 | M | Tonsillar hypertrophy | 1.7 | 7.1 | 3.0 | 84.5 | 2.3 | Negative |
| Child 2 | 3 | M | Tonsillar hypertrophy | 1.3 | 5.9 | 5.2 | 75.4 | 3.3 | Positive |
| Child 3 | 3 | M | Tonsillar hypertrophy | 1.5 | 2.8 | 2.5 | 70.7 | 13.3 | Negative |
| Child 4 | 3 | M | Tonsillar hypertrophy | 4.0 | 8.0 | 8.8 | 79.6 | 2.7 | Negative |
| Child 5 | 3 | F | Recurrent tonsillitis | 5.6 | 13.1 | 6.0 | 58.8 | 6.5 | Positive |
| Child 6 | 4 | M | Tonsillar hypertrophy | 0.6 | 3.2 | 2.6 | 88.6 | 1.2 | Positive |
| Child 7 | 4 | M | Recurrent tonsillitis | 1.5 | 4.3 | 2.4 | 85.9 | 0.8 | Positive |
| Child 8 | 4 | M | Tonsillar hypertrophy | 3.7 | 8.3 | 5.8 | 58.5 | 2.8 | Positive |
| Child 9 | 9 | F | Recurrent tonsillitis | 4.7 | 12.0 | 2.8 | 63.2 | 5.8 | Positive |
| Child 10 | 11 | F | Tonsillar hypertrophy | 7.5 | 10.7 | 0.8 | 78.1 | 1.5 | Positive |
| Mean (SD) in child’s group | 3.2 (2.2) | 7.5 (3.6) | 4.0 (2.4) | 74.3 (11.1) | 4.0 (3.7) | N/A | |||
| Adult 11 | 49 | M | Recurrent tonsillitis | 6.9 | 18.7 | 2.0 | 57.6 | 7.5 | Positive |
| Adult 12 | 52 | M | Recurrent tonsillitis | 7.8 | 18.1 | 4.9 | 55.8 | 2.3 | Positive |
| Mean (SD) in adult’s group | 7.3 (0.6) | 18.4 (0.4) | 3.4 (2.0) | 56.7 (1.3) | 4.9 (3.7) | N/A | |||
aData are provided per subject.
bFlow cytometric data are presented as % of LinnegHLA-DR+ cells gated as shown in Figure 1. Each DC population was defined as follows: tCD207 DCs are HLA-DR+ CD207+; CD1c DCs are HLA-DR+ CD11c+ CD1c+; CD141/Clec9A DCs are HLA-DR+ CD11c+ CD141+ Clec9A+; pDCs are HLA-DR+ CD304+; and macrophages are HLA-DR+ CD11c+ CD14+.
cEBV status was defined for each child by EBV serology interpretation and for adults by EBV DNA detection.
N/A, non-applicable.